Learn more

BIO MEGA BOEHRINGER INGELHEIM

Overview
  • Total Patents
    177
About

BIO MEGA BOEHRINGER INGELHEIM has a total of 177 patent applications. Its first patent ever was published in 1987. It filed its patents most often in United States, EPO (European Patent Office) and Israel. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are ARIZONA BIOMEDICAL RES COMMISS, DENDREON CORP and INST ORGANICHESKOGO SINTEZA AK.

Patent filings per year

Chart showing BIO MEGA BOEHRINGER INGELHEIMs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Deziel Robert 70
#2 Moss Neil 56
#3 Plante Raymond 34
#4 Anderson Paul Cates 31
#5 Lavallee Pierre 25
#6 Beaulieu Pierre Louis 25
#7 Simoneau Bruno 23
#8 Poupart Marc-Andre 19
#9 Halmos Teddy 19
#10 Jung Grace Lorena 18

Latest patents

Publication Filing date Title
CA2165996A1 Stereoselective preparation of 2-substituted succinic derivatives
US5550291A Process for key intermediates for HIV protease inhibitors
CA2139169A1 Antiherpes peptidomimetic compounds
US5614533A Substituted pipecolinic acid derivatives as HIV protease inhibitors
US5574015A Isosteric antiherpes peptide derivatives
JPH08501567A Renin-inhibited N- (2-amino-2-oxoethyl) butanediamide derivative
US5648337A Antiherpes pentapeptides
CN1096293A Replacement pipecolinic acid derivative as the hiv protease inhibitor
CN1096299A Antiherpes peptide derivatives with ureido N-terminus
CN1096300A Isosteric antiherpes peptide derivatives
CN1096292A The pyrrolidine derivatives as HIV protease inhibitors that replaces
CA2095408A1 Method of combating acyclovir-resistant herpes simplex viral infections
EP0560268A1 Substituted pipecolinic acid derivatives as HIV protease inhibitors
ZA9301777B Substituted pyrrolidine derivatives as HIV protease inhibitors.
US5258493A Cyclic peptides for treating herpes infections
US5376635A Fluorine containing atrial natriuretic peptides
CA2033448A1 Antiherpes compositions and method of use
NZ234373A Acylated n-terminal tetrapeptides having an esterified or amidified aspartic acid residue and optionally substituted at the c-terminal by 5-1h-tetrazolyl; use in treatment of herpes virus infections
EP0411334A1 Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain
EP0411333A1 Antiherpes tetrapeptide derivatives having a substituted aspartic acid side chain